Replimune Group (REPL) Q2 FY27 earnings call

Replimune marked a corporate transition with the early October commercial rollout of TUDRIQEV, its first approved RPx platform asset for PD-1 refractory melanoma. Commercial execution is prioritizing account onboarding across a 200-center initial footprint, while manufacturing readiness and capital resources are aligned to support launch operations and ongoing pivotal trials without near-term financing pressure.